L03AD · Antineoplastic and immunomodulating agents
Natalizumab Elan Pharma
Indications
Treatment of moderately to severely active Crohn's disease for the reduction of signs and symptoms, and the induction and maintenance of sustained response and remission, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or are intolerant to or have medical contraindications to such therapies.
Composition
- Active substance
- natalizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Natalizumab Elan Pharma
- Active substance
- natalizumab
- ATC code
- L03AD
- Therapeutic area
- Crohn Disease